tiprankstipranks
Advertisement
Advertisement

BYSI Stock Latest News

Beyondspring Delays Second Closings of Share Sale
Company AnnouncementsBeyondspring Delays Second Closings of Share Sale
4M ago
8K
BYSI
BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress
PremiumThe Fly
BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress
4M ago
BYSI
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC
PremiumThe Fly
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC
4M ago
BYSI
BeyondSpring Completes $2 Million Securities Agreement
PremiumCompany Announcements
BeyondSpring Completes $2 Million Securities Agreement
5M ago
8K
BYSI
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift
PremiumCompany Announcements
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift
5M ago
BYSI
BeyondSpring reports Q3 EPS (4c) vs (5c) last year
PremiumThe FlyBeyondSpring reports Q3 EPS (4c) vs (5c) last year
5M ago
BYSI
SEED Therapeutics Secures $6M in Series A-3 Financing
Premium
Company Announcements
SEED Therapeutics Secures $6M in Series A-3 Financing
7M ago
8K
BYSI
Beyondspring Shareholders Ratify Accounting Firm Appointment
Premium
Company Announcements
Beyondspring Shareholders Ratify Accounting Firm Appointment
7M ago
8K
BYSI
BeyondSpring’s Q2 2025: Clinical Advances and Strategic Moves
PremiumCompany Announcements
BeyondSpring’s Q2 2025: Clinical Advances and Strategic Moves
8M ago
BYSI
BeyondSpring reports Q2 EPS (10c) vs (4c) last year
PremiumThe Fly
BeyondSpring reports Q2 EPS (10c) vs (4c) last year
8M ago
BYSI
BeyondSpring announces publication of human clinical study on plinabulin
PremiumThe Fly
BeyondSpring announces publication of human clinical study on plinabulin
9M ago
BYSI
BeyondSpring presents interim phase 2 data on 303 study
PremiumThe Fly
BeyondSpring presents interim phase 2 data on 303 study
10M ago
BYSI
BeyondSpring Reports Q1 2025 Financials and Clinical Progress
PremiumCompany AnnouncementsBeyondSpring Reports Q1 2025 Financials and Clinical Progress
11M ago
BYSI
BeyondSpring’s 2024 Progress and Strategic Milestones
Premium
Company Announcements
BeyondSpring’s 2024 Progress and Strategic Milestones
1y ago
BYSI
BeyondSpring reports FY24 EPS (21c) vs. (34c) last year
Premium
The Fly
BeyondSpring reports FY24 EPS (21c) vs. (34c) last year
1y ago
BYSI
BeyondSpring announces expected 2025 milestones
PremiumThe Fly
BeyondSpring announces expected 2025 milestones
1y ago
BYSI
SEED receives FDA Rare Pediatric Disease, Orphan Drug designations for ST-01156
PremiumThe Fly
SEED receives FDA Rare Pediatric Disease, Orphan Drug designations for ST-01156
1y ago
BYSI
BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly
PremiumThe Fly
BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly
1y ago
LLY
BYSI
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
PremiumThe Fly
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
1y ago
BYSI
BeyondSpring presents final data analysis of DUBLIN-3 Phase 3 study
PremiumThe FlyBeyondSpring presents final data analysis of DUBLIN-3 Phase 3 study
2y ago
BYSI
BeyondSpring presented interim Phase 2 data on 303 Study
Premium
The Fly
BeyondSpring presented interim Phase 2 data on 303 Study
2y ago
MRK
BYSI
BeyondSpring announces Dublin-3 final phase 3 efficacy data
Premium
The Fly
BeyondSpring announces Dublin-3 final phase 3 efficacy data
2y ago
BYSI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >